CareDx, Inc (CDNA) P/E Ratio History
Historical price-to-earnings valuation from 2014 to 2025
Loading P/E history...
CDNA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, CareDx, Inc (CDNA) trades at a price-to-earnings ratio of -53.6x, with a stock price of $21.44 and trailing twelve-month earnings per share of $-0.15.
The current P/E is 124% below its 5-year average of 220.1x. Over the past five years, CDNA's P/E has ranged from a low of 12.2x to a high of 958.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, CDNA trades at a 340% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, CDNA trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CDNA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CDNA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $21B | 25.5Lowest | 6.01 | +171%Best | |
| $3B | 49.7 | - | +165% | |
| $2B | 29.5 | 4.40Best | +14% | |
| $176B | 26.8 | 12.67 | +7% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CDNA Historical P/E Data (2014–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $14.54 | $1.19 | 12.2x | -94% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $19.54 | $1.02 | 19.2x | -91% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $17.75 | $1.09 | 16.3x | -93% |
| FY2024 Q4 | $21.41 | $0.90 | 23.8x | -89% | |
| FY2015 Q1 | $5.54 | $0.01 | 423.3x | +92% | |
| FY2014 Q4 | Wed Dec 31 2014 00:00:00 GM | $7.25 | $0.08 | 87.2x | -60% |
| FY2014 Q3 | $7.00 | $0.01 | 958.9x | +336% |
Average P/E for displayed period: 220.1x
See CDNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CDNA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CDNA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCDNA — Frequently Asked Questions
Quick answers to the most common questions about buying CDNA stock.
Is CDNA stock overvalued or undervalued?
CDNA trades at -53.6x P/E, below its 5-year average of 220.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CDNA's valuation compare to peers?
CareDx, Inc P/E of -53.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is CDNA's PEG ratio?
CDNA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2014-2025.